Health News Archive - February 09, 2010
SEATTLE, Feb. 9 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration (the "FDA") informed CTI that due to severe weather conditions in the Washington, D.C.
PARIS, Feb. 9 /PRNewswire-FirstCall/ -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that it has successfully completed its tender offer for all outstanding shares of common stock of Chattem, Inc. (Nasdaq: CHTT).
BARCELONA, Spain, Feb.
LAUSANNE, Switzerland, February 9 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect.
UITHOORN, The Netherlands, February 9 /PRNewswire-FirstCall/ -- Hoya announces the appointment of Mr. Hans Werquin (49) as CEO of Hoya Vision Care Europe starting the 1st of April 2010. He will report to Mr. Gerald W. Bottero, who has been leading the European branch in the past 5 years.
TOKYO, Feb. 9 /PRNewswire/ -- ALOKA CO., LTD. announced that the ProSound Alpha 6, the company's recently introduced compact, yet versatile and ergonomic diagnostic ultrasound system, was presented the iF Product Design Award 2010.
WAYNE, N.J., Feb. 9 /PRNewswire/ -- Today, Toys"R"Us, Inc. and the Toys"R"Us Children's Fund announced they have expanded their support of Autism Speaks to include a fundraising campaign in all of the company's stores in North America.
QUAKERTOWN, Pa., Feb. 9 /PRNewswire/ -- "I knew he was the one for me when he held my hand without flinching, even when I tried to pull away out of embarrassment.
LONDON, Feb. 9 /PRNewswire/ -- Biomarker analysis market has excellent growth potential. The 'omics' revolution of the last decade has ensured that the field of biomarker research will test the frontiers of biomedical research in the coming years.
ST. LOUIS, Feb. 9 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced its financial results for the quarter and year ended December 31, 2009. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations.